NPM1 and acute myeloid leukemia: Our clinical results are supported by recent in vitro data in cell lines and primary AML blasts showing the ability of ATRA to induce a significant amount of apoptosis in some (3 out of 11) primary leukemia samples from patients with NPM1 mutation which was potentiated by combination with ATO [13].